Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Arte... (w in coronary arteries unless their rupt...)

Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease

Date:9/24/2009

w in coronary arteries unless their rupture results in a clot.

Among the findings of the 700-patient study, researchers were able to identify the common characteristics of lesions that put patients at highest risk for future cardiac events by using advanced imaging called virtual histology intravascular ultrasound (VH(R) IVUS) and standard angiography. Going forward, investigators will now have access to more than 40,000 datapoints derived from 150 variables within each of the patients, far beyond the level of assessment of previous interventional studies.

"While the prognosis of patients with acute coronary syndromes undergoing successful stenting and treated with contemporary medical therapy is favorable, we are now able to identify those lesion types with a significantly increased likelihood of causing future cardiovascular events," Stone said.

The PROSPECT study recruited patients who were in need of a PCI (percutaneous coronary intervention) to treat a heart attack or threatened heart attack. Patients consented to collection of additional data as follow-up to their procedure, including VH IVUS imaging and standard angiography. PROSPECT collected data about characteristics of vulnerable plaque lesions that were present but not causing symptoms at the time of the procedure. The goal was to correlate lesion characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.

Study Findings

In the study, approximately 20 percent of the patient population experienced a major adverse cardiac event (cardiac death, cardiac arrest or heart attack) within three years of enrollment. Half of these events can be attributed to the original "culprit" lesions (those treated with PCI) and half to previously untreated,
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:

Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Arte...(w in coronary arteries unless their rupt...),Health